I second the KRAS kickers site. I am also in a group chat with REV MED clinical trial participants since I was one. Many people have had long lasting, stabilizing results. There is a KRAS G12D specific drug as well as one that is used against all KRAS “varieties”.
It is being tested on many Pcancer patients as well as NSCLC patients. I cannot tell from discussions which are having better results. We are being told by many sources that the pan KRAS drug, now named Doraxasonib(or similar!) will be released this year. This is why many trials are concluding. However, they are continuing some trials where it is being tested in combination with current therapies like Gemcitabine.
It stabilized and shrunk my target tumor for about 5 months then I chose to hop off it and have targeted radiation while it was small. I was in a phase 1 trial with both drugs, so the appropriate dosing had not yet been set. I am KRAS G12D, TP53, and ATM. No genetic mutations known.